4th How to Diagnose and Treat
Multiple Myeloma
April 14-16, 2023 – Berlin, Germany
Chairs: Hermann Einsele (Würzburg), Irene Ghobrial (Boston), Maria-Victoria Mateos (Salamanca)

Friday, April 14, 2023

08:30-08:40 Welcome

SESSION I – How I treat smoldering myeloma (SMM)
Chair: Elizabeth O'Donnell (Boston)

08:40-08:55	Interactive case: Smoldering myeloma	Maria-Victoria Mateos (Salamanca)
08:55-09:00	*Discussion*	
09:00-09:20	Case-based lecture: High risk smoldering myeloma	Elizabeth O'Donnell (Boston)
09:20-09:25	*Discussion*	
09:25-09:45	Case-based lecture: Understanding the immune microenvironment smoldering myeloma	Madhav Dhodapkar (Atlanta)
09:45-09:50	*Discussion*	
09:50-10:10	Case-based lecture: Imaging with PET-CT in SMM	Elena Zamagni (Bologna)
10:10-10:15	*Discussion*	
10:15-10:20	Brief oral communication *Modeling dynamic evolution of multiple myeloma studying cell populations metabolism and competition under maximum power constraints: a systems-thinking based approach*	*Alessandra Romano (Catania)*
10:20-10:23	*Discussion*	
10:23-10:45	*Panel discussion*	

10:45-11:15 Coffee Break

SESSION II – How I treat newly diagnosed multiple myeloma
Chair: Maria-Victoria Mateos (Salamanca)

11:15-11:22	Interactive case: Newly diagnosed transplant eligible multiple myeloma	Charlotte Pawlyn (London)
11:22-11:25	*Discussion*	
11:25-11:45	Case-based lecture: Do we still need transplant in the first-line therapy?	Omar Nadeem (Boston)
11:45-11:50	*Discussion*	

11:50-12:10 Case-based lecture: How to treat the frail patient — Sonja Zweegman (Amsterdam)
12:10-12:15 *Discussion*

12:15-12:35 Case-based lecture: Novel therapeutic approaches for frail multiple myeloma patients — Alessandra Larocca (Turin)
12:35-12:40 *Discussion*

12:40-12:47 Interactive case: Newly diagnosed transplant-ineligible patient — Siobhan Glavey (Dublin)
12:47-12:50 *Discussion*

12:50-12:55 Brief oral communication — *Marko Mitrović (Belgrade)*
Extramedullary multiple myeloma: is there an effective treatment approach?
12:55-12:58 Discussion

12:58-13:20 Panel discussion

13:20-15:15 Lunch

14:05-15:05 **SATELLITE SYMPOSIUM**
From clinical trials to real world practice: the role of anti-BCMA treatments in relapsed/refractory multiple myeloma
Chair: Stefan Knop (Nuremberg)
Speakers: Elena Zamagni (Bologna), Leo Rasche (Würzburg), Stefan Knop (Nuremberg)

This event is organised and sponsored by GSK and is intended for healthcare professionals with an interest in multiple myeloma

SESSION III – From risk stratification to risk-based therapy?
Chair: Hermann Einsele (Würzburg)

15:15-15:22 Interactive case: How I diagnose the high-risk patient — Faith Davies (New York)
15:22-15:25 *Discussion*

15:25-15:45 Case-based lecture: Should the high-risk patient be treated differently? — Faith Davies (New York)
15:45-15:50 *Discussion*

15:50-16:10 Case-based lecture: Should we add immunotherapy in high-risk patients? — Leo Rasche (Würzburg)
16:10-16:15 *Discussion*

16:15-16:35 Case-based lecture: Precision medicine in multiple myeloma — Marc Raab (Heidelberg)
16:35-16:40 *Discussion*

16:40-16:47 Interactive case: How I treat a high-risk MM patient in the first line — Stefan Knop (Nuremberg)
16:47-16:50 *Discussion*

16:50-16:55 Brief oral communication — *Tengyao Song (Sunnyvale)*
Identify chromosome translocation of circulating plasma cells by Cepheid GeneXpert automated RT-qPCR without flow cytometry and FISH staining
16:55-16:58 Discussion

16:58-17:20 *Panel discussion*

17:20-17:50 ***Coffee break***

17:50-18:30 **DEBATE 1 – Should we use MRD testing to determine therapy in multiple myeloma?**
Chair : Maria-Victoria Mateos (Salamanca)

Audience votes

17:50-18:05 YES — Noemi Puig (Salamanca)

18:05-18:20 NO — Heinz Ludwig (Vienna)

18:20-18:30 *Discussion*

Audience votes again

18:30-19:10 **DEBATE 2 – Is CAR T cell therapy replacing autologous SCT?**
Chair: Hermann Einsele (Würzburg)

Audience votes

18:30-18:45 YES — Salomon Manier (Lille)

18:45-19:00 NO — Francesca Gay (Turin)

19:00-19:10 *Discussion*

Audience votes again

19:10-20:20 ***Poster Walks and Welcome Get Together stand-up buffet dinner***
Poster Walk Leaders: Elizabeth O'Donnell (Boston), Leo Rasche (Würzburg)

Saturday, April 15, 2023

07:45-08:45 **3 Simultaneous Meet the Expert sessions**

1. How to sequence therapy in RRMM — Xavier Leleu (Poitiers)
2. Role of MoAb in first-line therapy — Shonali Midha (Boston)
3. How to manage infections in MM patients — Heinz Ludwig (Vienna)

08:50-09:50 **SATELLITE SYMPOSIUM**
On the case: Practical discussions and clinical decisions in managing hard-to-treat multiple myeloma populations
Chair: Stefan Knop (Nuremberg)
Speakers: Ceri Bygrave (Cardiff), Stefan Knop (Nuremberg), Albert Oriol (Barcelona)

This symposium is organised and sponsored by Sanofi

09:50-10:20 ***Coffee Break and Poster viewing***

SESSION IV – How I treat relapsed multiple myeloma
Chair: Maria-Victoria Mateos (Salamanca)

10:30-10:37	Interactive case: Relapsed multiple myeloma	Xavier Leleu (Poitiers)
10:37-10:40	*Discussion*	
10:40-11:00	Case-based lecture: How I treat first relapse	Katja Weisel (Hamburg)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture: How to use T cell engagers in relapse multiple myeloma?	Maria-Victoria Mateos (Salamanca)
11:25-11:30	*Discussion*	
11:30-11:50	Case-based lecture : Novel agents in relapsed multiple myeloma (Selinexor, Belantamab, Venetoclax, etc)	Michel Delforge (Leuven)
11:50-11:55	*Discussion*	
11:55-12:02	Interactive case: Optimal sequence at relapse	Enrique Ocio (Santander)
12:02-12:05	*Discussion*	
12:05-12:10	Brief oral communication *Effectiveness and safety of belantamab mafodotin in patients with relapsed/refractory multiple myeloma in real-life setting: the ALFA study*	*Xavier Leleu (Poitiers)*
12:10-12:13	*Discussion*	
12:13-12:25	*Panel discussion*	

12:35-14:25 Lunch

13:15-14:15 SATELLITE SYMPOSIUM
Treatment choices in early RRMM: an expert discussion
Chair: Marc Raab (Heidelberg)
Speakers: Francesca Gay (Turin), Martin Kortüm (Würzburg), Marc Raab (Heidelberg)

Satellite Symposium sponsored by Celgene, a Bristol Myers Squibb company.

14:25-15:05 DEBATE 3 – Cell free DNA / circulating tumor cells to replace BM-biopsy and MRD measurement
Chair: Martin Kortüm (Würzburg)

Audience votes

14:25-14:40	YES	Noemi Puig (Salamanca)
14:40-14:55	NO	Omar Nadeem (Boston)
14:55-15:05	*Discussion*	

Audience votes again

15:05-15:30 Coffee break and Poster Viewing

SESSION V- You can't be immune for immune therapy anymore
Chair: Hermann Einsele (Würzburg)

15:30-15:37	Interactive case: How to use novel immunotherapies	Hermann Einsele (Würzburg)
15:37-15:40		
15:40-16:00	Case-based lecture: CART in multiple myeloma	Omar Nadeem (Boston)
16:00-16:05	*Discussion*	
16:15-16:35	Case-based lecture: Novel targets for CAR T cells in multiple myeloma	Maik Luu (Würzburg)
16:35-16:40	*Discussion*	
16:40-17:00	Case-based lecture: Bi- and trispecific antibodies	Hermann Einsele (Würzburg)
17:00-17:05	*Discussion*	
17:05-17:25	Case-based lecture: How to predict outcome of CAR T cell and T cell Engager treated patients	Paola Neri (Calgary)
17:25-17:30	*Discussion*	
17:30-17:50	Case-based lecture: Role of antigen loss in CAR T cell engaging antibodies	Adam Sperling (Boston)
17:50-17:55	*Discussion*	
17:55-18:00	Brief oral communication *Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: final analysis of the DREAMM-2 trial*	*Martin Kortüm (Würzburg)*
18:00-18:03	*Discussion*	
18:03-18:35	*Panel discussion*	

Sunday, April 16, 2023

07:45-08:45 3 Simultaneous Breakfast Meet the Expert Sessions

1. How to use genetics in multiple myeloma	Faith Davies (New York)
2. Novel agents (not immunal therapy)	Fredrik Schjesvold (Oslo)
3. Novel agents (immunal therapy)	Paola Neri (Calgary)

08:55-09:55 SATELLITE SYMPOSIUM

Exploring a Fractured Timeline of Different Decisions: How Can We Optimise Outcomes in Multiple Myeloma?
Chair: Philippe Moreau (Nantes)
Speakers: Philippe Moreau (Nantes), Paula Rodriguez-Otero (Pamplona), Katja Weisel (Hamburg)

This symposium is organized by PeerVoice and supported by an educational grant from GSK plc.

10:05-10:30 Keynote lecture: The future of multiple myeloma
Chair: Kenneth C. Anderson (Boston)

10:05-10:25	MM treatment in 2030	Kenneth C. Anderson (Boston)

10:25-10:30 *Discussion*

SESSION VI – Other plasma cell dyscrasias
Chair: Fredrik Schjesvold (Oslo)

10:30-10:37	Interactive case: How I treat Waldenstrom's macroglobulinemia	Jorge Castillo (Boston)
10:37-10:40	*Discussion*	
10:40-11:00	Case-based lecture: How I treat amyloidosis	Mario Nuvolone (Pavia)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture: Is this myeloma kidney? A case of significantly elevated free serum light chains and kidney failure	Fredrik Schjesvold (Oslo)
11:25-11:30	*Discussion*	
11:30-11:50	Case-based lecture: Bone disease in multiple myeloma	Elizabeth O'Donnell (Boston)
11:50-11:55	*Discussion*	
11:55-12:02	Interactive case: Supportive care in multiple myeloma today	Martin Kortüm (Würzburg)
12:02-12-05	*Discussion*	
12:05-12:35	*Panel discussion*	
12:35-12:45	***Closing remarks***	

MEETING CLOSURE